

31 August 2021

**Diaceutics PLC**  
**("Diaceutics" or the "Group" or the "Company")**

**Investor Presentation**

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, today announces that Peter Keeling, CEO, and Philip White, CFO, will provide a live presentation relating to the Company's Interim results for the six months ending 30 June 2021 via the Investor Meet Company platform on 15 September 2021 at 3:30pm.

The presentation is open to all existing and potential shareholders and registration can be completed via the following link:

<https://www.investormeetcompany.com/diaceutics-plc/register-investor>

Questions should be submitted by 9am on 14 September 2021 through the Investor Meet Company dashboard or at any time during the live presentation.

Investors who already follow Diaceutics on the Investor Meet Company platform will automatically be invited.

**Enquiries:**

**Diaceutics PLC**

Philip White, Chief Financial Officer

Via Alma PR

**Stifel Nicolaus Europe Limited (Nomad & Broker)**

Ben Maddison  
Stewart Wallace  
Nick Adams

Tel: +44 (0)20 7710 7600

**Alma PR**

Caroline Forde  
Robyn Fisher  
Kieran Breheny  
Matthew Young

Tel: +44(0)20 3405 0205  
diaceutics@almapr.co.uk

**About Diaceutics**

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DOCXBLFXFVLBBBL